Brief: Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026
13/01/2026 13:09
Jan 13 (Reuters) - Edgewise Therapeutics Inc EWTX.O: EDGEWISE THERAPEUTICS PROVIDES CORPORATE UPDATES AND HIGHLIGHTS PRIORITIES FOR 2026 EDGEWISE THERAPEUTICS INC - ANTICIPATE PHASE 2 RESULTS FOR EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY (HCM) IN FIRST HALF OF 2026 EDGEWISE THERAPEUTICS INC - PREPARE FOR NDA SUBMISSION FOR SEVASEMTEN IN BECKER IN H1 2027 EDGEWISE THERAPEUTICS INC - TO INITIATE EDG-7500 PHASE 3 TRIAL IN INDIVIDUALS WITH OBSTRUCTIVE AND NONOBSTRUCTIVE HCM IN SECOND HALF OF 2026 Source text: ID:nPn9hkJyTa Further company coverage: EWTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending